Processa Pharmaceuticals Inc. announced the completion of enrollment and dosing of 20 patients for the planned formal interim analysis in its ongoing Phase 2 clinical study of NGC-Cap, a proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. The randomized trial compares NGC-Cap with standard capecitabine monotherapy in patients who have received at least one prior cancer treatment. The interim analysis will evaluate comparative safety and efficacy outcomes between the two treatment arms and is expected to be completed in the first quarter of 2026. Results from this interim analysis have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Processa Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619501-en) on January 05, 2026, and is solely responsible for the information contained therein.